KSL Diagnostics has launched the COVID-19 Immune Index, a new antibody test that can monitor the level of virus protection against the disease.
The test has been designed for measuring the immune response of an individual to Covid-19 and evaluating the infection risk.
It measures antibodies that are specific to Covid-19, which develop in response to vaccination or infection.
The COVID-19 Immune Index helps monitor virus protection effectiveness using a blood test and correlates virus neutralisation against the antibody levels of an individual.
The blood test provides accurate, quantitative results to physicians so they can make decisions regarding the time for booster vaccine doses.
KSL Diagnostics president and CEO Kevin Lawson said: “There is a lot of variability in antibody levels over time after infection, vaccination and boosters. Guidance is constantly changing, but good tools to help people better understand their immune status have not been available.
“The COVID-19 Immune Index provides an accurate report for those who are immunocompromised, at risk with co-morbidities, re-entering the workplace or travelling. Understanding your level of immunity can provide peace of mind as we move past the pandemic.”
The company stated that the blood test helps to monitor the immunity levels of patients undergoing treatment for organ transplants, cancer or serious chronic illnesses.
Furthermore, the new antibody test already received approval from the New York State Department of Health/CLIA/Emergency Use Authorization (EUA).
Last month, the New York State Department of Health (NYSDOH) granted conditional approval to KSL Diagnostics’ EXACT COVID-19 Antibody Test.